MedTrace Logo

A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects

NCT00664183 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2009-10-20

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of Vitreosolve in diabetic retinopathy patients.

Conditions

Interventions

DRUG

Vitreosolve

Intravitreal injection

Sponsors & Collaborators

  • Vitreoretinal Technologies, Inc.

    lead INDUSTRY

Principal Investigators

  • Baruch Kupperman, MD · University of California, Irvine

  • Naresh Mandova, MD · University of Colorado, Denver

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-12-31

Countries

  • United States
  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00664183 on ClinicalTrials.gov